Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Income from Continuing Operations (2016 - 2025)

Viridian Therapeutics, Inc.\DE has reported Income from Continuing Operations over the past 12 years, most recently at 118239000.0 for Q4 2025.

  • Quarterly results put Income from Continuing Operations at 118239000.0 for Q4 2025, down 48.79% from a year ago — trailing twelve months through Dec 2025 was 340938000.0 (down 26.51% YoY), and the annual figure for FY2025 was 340944000.0, down 26.45%.
  • Income from Continuing Operations for Q4 2025 was 118239000.0 at Viridian Therapeutics, Inc.\DE, down from 35052000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for VRDN hit a ceiling of 14043000.0 in Q3 2021 and a floor of 118239000.0 in Q4 2025.
  • Median Income from Continuing Operations over the past 5 years was 48101000.0 (2023), compared with a mean of 52865950.0.
  • Peak annual rise in Income from Continuing Operations hit 68.11% in 2021, while the deepest fall reached 177.74% in 2021.
  • Viridian Therapeutics, Inc.\DE's Income from Continuing Operations stood at 28946000.0 in 2021, then crashed by 58.17% to 45785000.0 in 2022, then crashed by 45.61% to 66667000.0 in 2023, then fell by 19.2% to 79469000.0 in 2024, then plummeted by 48.79% to 118239000.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 118239000.0 (Q4 2025), 35052000.0 (Q3 2025), and 100735000.0 (Q2 2025) per Business Quant data.